康替唑胺片 | China Drugs ListContezolid Tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 感染性疾病Infectious diseases
- 公开来源记录的适应症
- 本品适用于治疗由对本品敏感的金黄色葡萄球菌(甲氧西林敏感和耐药的菌株)、化脓性链球菌或无乳链球菌引起的复杂性皮肤和软组织感染。为减少细菌耐药的发生,确保康替唑胺及其他抗菌药物的疗效,本品应仅用于治疗已确诊或高度怀疑由敏感菌引起的感染。本品不适用于治疗革兰阴性菌感染。如确诊或怀疑合并有革兰阴性菌感染,建议联合应用抗革兰阴性菌药物进行治疗。在选择或调整抗菌药物治疗方案时,应考虑进行细菌培养和药敏试验以分离并鉴定感染病原菌,确定其对本品的敏感性。如果没有这些试验的药敏数据做参考,则应根据当地细菌耐药性和抗菌药物敏感性等流行病学情况进行经验性治疗。在获得以上药敏结果之前可以先使用本品进行治疗,获得药敏结果后再选择进行针对性的病原治疗。For complicated skin and soft-tissue infections caused by susceptible Staphylococcus aureus (methicillin-susceptible or methicillin-resistant strains), Streptococcus pyogenes or Streptococcus agalactiae. To reduce the development of bacterial resistance and preserve the effectiveness of contezolid and other antibacterials, it should be used only for infections proven or strongly suspected to be caused by susceptible bacteria. It is not indicated for Gram-negative infections. If a concurrent Gram-negative infection is confirmed or suspected, combination treatment with an agent active against Gram-negative bacteria is recommended. Bacterial culture and susceptibility testing should be considered when selecting or adjusting treatment, to isolate and identify the pathogen and determine its susceptibility. If susceptibility results are unavailable, empiric treatment should follow local epidemiological information on bacterial resistance and antibacterial susceptibility. Treatment may begin before susceptibility results are available, then be adjusted to targeted treatment once results are obtained.
- 适应症来源与口径
- 来源日期： 2025, 2026. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 适应症已与官方公开申报资料核对。尚未取得完整原始说明书。Indications checked against an official public submission. The full original prescribing information is still unavailable.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限对本品敏感的金黄色葡萄球菌(甲氧西林敏感和耐药的菌株)、化脓性链球菌或无乳链球菌引起的复杂性皮肤和软组织感染。Limited to complicated skin and soft-tissue infections caused by susceptible Staphylococcus aureus (methicillin-susceptible or methicillin-resistant strains), Streptococcus pyogenes or Streptococcus agalactiae.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.